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Genetic predisposition to human lung cancer
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Summary The influence of polymorphic variants of the human c-Ha-ras gene on predisposition to lung
cancer has been investigated. The human c-Ha-ras gene has been shown to reside on a polymorphic BamH1
restriction fragment. This restriction fragment length polymorphism (RFLP) results from variation in the size
of a region of repetitive DNA 3' to the gene. An attempt has been made to characterise and compare the c-
Ha-ras RFLP's in a normal population and in a group of cancer patients. DNA was extracted from the white
blood cells of 101 normal donors and four common Ha-ras alleles identified, with occasional rare alleles of
various sizes. The allele frequencies were examined in 132 lung cancer patients, comprising 66 individuals with
small cell carcinoma of the lung (SCCL) and 66 with non-small cell carcinoma of the lung (non-SCCL). An
abnormal allele distribution was found in individuals with non-SCCL compared to both control and SCCL
values, suggesting a degree of genetic pre-disposition to non-SCCL. In addition, analysis of the Ha-ras
RFLP's in solid lung tumour samples inferred a deletion of material from the short arm of chromosome 11 in
two of 16 informative samples.
Mutation of cellular ras genes in the region of
codons 12 or 61 has been shown to activate them,
with respect to cellular transformation (Reddy et
al., 1982; Yuasa et al., 1983). However,
mutationally activated ras genes appear to be
present in only a minority of naturally occurring
human tumours (Slamon et al., 1984; Fujita et al.,
1984). Goldfarb et al. (1982) showed that the
human c-Ha-ras gene is located on a BamH 1
fragment of variable length. Capon et al. (1983)
showed that the size difference between alleles
mapped into a region of DNA consisting of tandem
repeats of a 28 base pair (bp) consensus sequence,
approximately one kilobase (kb) 3' of the poly-
adenylation signal of the gene (Figure 1). It seems
likely that changes in the number of tandem repeat
units are responsible for the RFLP's. Krontiris et
al. (1985) characterised the c-Ha-ras RFLP
frequency in groups of mixed cancer patients and
unaffected individuals. They found that there were
four common alleles of 6.9, 7.5, 8.0 and 8.3kb and
occasional rare alleles that differed in length from
the common alleles by up to 300 bp. The incidence
of rare alleles was significantly higher in cancer
patients than the normal population suggesting that
these alleles predisposed to cancer.
In this study the c-Ha-ras polymorphism has
been characterised in an unaffected population and
the allele frequency compared to that in two groups
of lung cancer patients.
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Figure 1 Schematic representation of the BamHl
fragment carrying the human c-Ha-ras gene. The open
boxes represent exons and the hatched box, the region
of tandem repeats. The cloned sequence in pT24-C3 is
represented by the solid line and flanking genomic
DNA by the broken line.
Materials and methods
Subjects
DNA was extracted from blood samples from 101
unaffected individuals and from blood and solid
tumour samples from 132 lung cancer patients. The
cancer patients were divided into those with SCCL
(66) and non-SCCL (66), comprising 56 patients
with squamous cell carcinoma of the lung (SQCCL)
and 10 with adenocarcinoma (ACL) of the lung.
DNA extractions
DNA was extracted from 10ml blood samples by
the method of Kunkel et al. (1977) and from the
solid tumour samples (25 of 66 non-SCCL cases) as
described by Heighway and Hasleton (1986).
Plasmid DNA
Plasmid DNA was purified by the method of
Humphries et al. (1975). Plasmids used were:
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(a) pT24-C3 carrying a 6.6kb BamHl fragment
encoding the c-Ha-ras gene and region of
tandem repeats (Reddy et al., 1982).
(b) Human fl-globin gene fragment cloned on a
4.4kb Pstl fragment in pBR322 (Orkin et al.,
1982).
(c) phTB3 encoding the human calcitonin gene
(Allison et al., 1981).
Southern analysis
Genomic DNA (10/pg) was digested with the stated
restriction endonuclease and electrophoresed in a
0.8% agarose gel. The DNA was blotted onto
nitrocellulose by the method of Southern (1975).
Plasmid DNA was nick translated using 32P to a
specific activity of 2x 108 c.p.m.,ug1 (Rigby et al.,
1977). Hybridisation, washing and autoradiography
were carried out as described by Maniatis et al.
(1982). Fragment sizes were determined by
comparison to a A phage DNA marker, digested
with Hind III, 32P labelled and co-electrophoresed
with the genomic samples.
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Figure 2 Southern analysis of BamHI digests of
human DNA probed with pT24-C3. Ha-ras allele
pattern (b) al, a4; (c) al, a3; (d) al, a2; (e) al, al; (a) A
DNA marker.
Statistical analysis
Statistical analysis was carried out using Chi
squared tests.
Results
To characterise the Ha-ras RFLP in the normal
population the test DNA was digested with BamHl
and probed in a series of Southern blots with nick
translated pT24-C3. Four common alleles were
identified corresponding to BamHl fragment sizes
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of 6.9, 7.4, 8.0 and 8.4kb and denoted al, a2, a3,
a4 respectively (Figure 2). Rare alleles were
detected at low frequency, with sizes ranging
between 7.0 and 8.7kb. To show that the apparent
variation in fragment size was due to a change in
fragment length and not to mutations in restriction
enzyme recognition sites, the procedure was
repeated using a second enzyme PvuII (Figure 3).
This enzyme gave two strongly hybridizing bands
with each Ha-ras allele one constant 2.6kb band
(fragment 1) and a second band corresponding to
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Figure 3 Southern analysis of PvuII digested human DNA probed with pT24-C3. Track (a) A DNA digested
with Hind III (b-f) genomic DNA showing various allele patterns. For fragments 1 and 2 refer to Figure 1.GENETIC PREDISPOSITION TO HUMAN LUNG CANCER 455
the fragment carrying the region of tandem repeats,
with a variable molecular weight (fragment 2). This
fragment was either 2.7, 3.2, 3.8 or 4.2kb in length
corresponding to the four common alleles or had a
value between 2.8 and 4.5kb for rare alleles. In 50
normal samples and 15 lung cancer patient samples
the same allele pattern was identified in both
BamHl and PvuII digests. As polymorphism was
not observed at either recognition site future
samples were screened with PvuII alone.
The allele frequencies observed in the unaffected
control population and the two groups of lung
cancer patients are shown in Table I. There was no
significant difference in allele frequency between
solid tumour and peripheral blood DNA samples in
the cancer patients. The number of individuals
carrying rare alleles in the unaffected population
was 9/101 (9%) and in the cancer patients, SCCL
7/66 (10%), non-SCCL 8/66 (12%). There is
therefore no significant difference between
individuals in these groups and it appears that rare
Ha-ras alleles do not pre-dispose individuals to lung
cancer. The frequencies of the al, a2, a3 alleles are
also not significantly different between the three
groups. However, Table II shows that the a4 allele
is present at a significantly higher level in the non-
SCCL group when compared to the unaffected
controls (P<0.05) and the SCCL group (P<0.004).
To ascertain if the higher level of the a4 allele in
non-SCCL patients was a tumour specific change,
matched tumour and peripheral blood or tumour
and normal lung tissue samples were obtained from
15 patients. No allele pattern difference was
observed between normal and tumour tissue
suggesting that peripheral blood DNA reflected
tumour allele phenotype and that the high level of
the a4 allele was not due to a change in the repeat
region length during tumour evolution. It therefore
appears that the presence of the a4 allele pre-
disposes an individual to SQCCL and ACL.
However, two of the tumour samples (SQCCL)
with allele patterns of al, a4 (patient A) and a2, a4
(patient B) showed their non-a4 bands to be greatly
reduced in hybridisation intensity (Figure 4).
Normal tissue was unobtainable for patient A but
examination of normal lung tissue from patient B
showed a normal a2, a4 pattern. It therefore
appeared that all or most of the tumour cells of
these patients had lost material from the short arm
of chromosome 11, the location of the Ha-ras gene.
The faint hybridisation to the deleted allele band is
probably due to the normal cells within the tumour.
Polymorphic probes inferred an apparent deletion
extending at least as far as the calcitonin gene at
lpl4 in patient A. In the second tumour the
deletion did not extend to the fi globin gene at
1lpl5.3 and may therefore have involved only the
very end of chromosome 11 or the H-ras gene
alone (data not shown). Out of 16 informative
(heterozygote) non-SCCL tumour DNA samples, of
Table I Ha-ras allele frequencies in human lung cancer.
Size of
BamHJ fragment Unaffected Small cell Non-small cell
(kb) controls carcinoma carcinoma
al 6.9 120 (60) 88 (67) 74 (56)
a2 7.4 32 (16) 15 (11) 13 (10)
a3 8.0 26 (13) 17 (13) 17 (13)
a4 8.4 15 (7) 5 (4) 19 (14)
Rare 9 (4) 7 (5) 9 (7)
202 132 132
Figures in brackets are percentages of the totals. It should be noted that the table
refers to allele frequencies and not to individuals carrying the various alleles.
Table II Individuals carrying the a4 Ha-ras allele.
Unaffected controls
Small cell carcinoma of
the lung
Non-small cell carcinoma of
the lung
15/101
5/66
19/66
(15%o)
(8%) P<0.05
(29%)
Values given are for individuals carrying the a4 allele, irrespective of the second allele.
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Figure 4 Southern analysis of DNA from 2 SQCCL
tumours showing deleted Ha-ras alleles. Patient A (a)
BamH 1 digest; (b) PvuII. digest. Patient appears to
have partially lost an al allele band. PvuII digests of
genomic DNA from and Patient B show loss of the a3
allele in the tumour sample (c) but not the normal
lung DNA (d).
various allele patterns, two were found to have loss
of material from the short arm of chromosome 11.
Dicussion
Krontiris et al. (1985) characterised the Ha-ras
polymorphisms in a mixed group of cancer patients
and unaffected individuals. They showed that Ha-
ras variants were inherited in a Mendelian manner
with polymorphic fragments segregating as
independent alleles. This study confirms the
findings of Krontiris et al. as regards the unaffected
population. Four common alleles were identified,
with rare variants and the sizes and frequency of all
polymorphic alleles were in close agreement with
the previous findings. However, in this study an
elevated level of rare alleles was not found in a
group of lung cancer patients.
Human lung cancer can be divided into two main
groups, (a) SCCL, a tumour that metastasises
relatively early in tumour development and
responds relatively well to chemotherapy and (b)
non-SCCL which does not respond as well to
chemotherapy and which can be further subdivided
into squamous cell carcinoma (SQCCL), adeno-
carcinoma (ACL) and large cell carcinoma of the
lung. This study shows that individuals with an a4
Ha-ras allele have a significantly greater chance of
developing non-SCCL (SQCCL and ACL) than
individuals not carrying it. The number of patients
with non-SCCL who carried the a4 allele was 19/66
(29%) compared to 15/101 (15%) in unaffected
individuals and 5/66 (8%) of SCCL patients. It is
potentially interesting that the group of SCCL
patients had approximately half the control
frequency of individuals with an a4 allele (8%
compared to 15%). Individuals at high risk of lung
cancer (e.g. smokers) who carry the a4 allele
therefore have a greater chance of contracting non-
SCCL. In a group at high risk, who have not
contracted non-SCCL a lower frequency of
individuals with an a4 allele might be expected.
SCCL patients represent such a group and the
frequency of the a4 allele is lower, although not
significantly with current numbers, than the control
group (P<0.25).
The fact that the rare allele frequency is not
significantly different between the three groups is
not in direct contradiction to the work of Krontiris
et al. This study deals specifically with lung cancer
patients while the patients in the previous study
had a range of different malignancies. It is therefore
possible that rare alleles predispose to some cancers
but not others, as would seem to be the case with
the a4 allele. Krontiris et al. (1985) reported that
deletion of the region of tandem repeats from the
cloned activated Ha-ras oncogene reduced efficiency
of transformation after transfection. Deletion of
this region was also found to reduce expression of
the gene (Seeburg et al., 1984). It is possible that
variation in the size of the repeat region may alter
expression or control of the Ha-ras gene which may
in turn predispose certain cell types to malignancy.
An apparent loss of the non-a4 allele in tumour
tissue from 2 out of 16 non-SCCL patients was
observed. Fearon et al. (1985) showed loss of
material from the short arm of chromosome 11 in
five out of 12 transition cell carcinomas of the
bladder and ureter, using the Ha-ras or insulin
polymorphic probes. It appears that tumour cells of
some non-SCCL have also lost llp material.
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